Tislelizumab
- Generic Name
- Tislelizumab
- Brand Names
- Tevimbra, Tizveni
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1858168-59-8
- Unique Ingredient Identifier
- 0KVO411B3N
- Background
Tislelizumab is under investigation in clinical trial NCT02660034 (The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Subjects With Advanced Solid Tumors).
- Indication
⑴用于治疗至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤（R/R cHL）患者。
⑵用于治疗局部晚期或转移性尿路上皮癌。
⑶联合化疗用于治疗一线晚期非鳞状非小细胞肺癌（NSCLC）患者。
⑷用于治疗既往接受过治疗的不可切除肝细胞癌患者。
⑸用于治疗晚期恶性实体瘤
- Associated Conditions
- -
- Associated Therapies
- -
Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer
- First Posted Date
- 2023-04-12
- Last Posted Date
- 2023-07-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT05809895
Tislelizumab Monotherapy or Combined With Lenvatinib as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma.
- Conditions
- Interventions
- First Posted Date
- 2023-04-11
- Last Posted Date
- 2023-04-11
- Target Recruit Count
- 50
- Registration Number
- NCT05807776
Neoadjuvant Immunotherapy Combined With Chemotherapy in Patients With Locally Advanced ESCC
- Conditions
- Interventions
- First Posted Date
- 2023-04-11
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05807542
- Locations
- 🇨🇳
ShanghaiZhongshan, Xiamen, Fujian, China
Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-04-05
- Last Posted Date
- 2023-04-05
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 23
- Registration Number
- NCT05799443
Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemotherapy as First-line Treatment for Participants With Locally Advanced or Metastatic NSCLC.
- First Posted Date
- 2023-03-30
- Last Posted Date
- 2023-07-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT05791097
A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-03-29
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- HiFiBiO Therapeutics
- Target Recruit Count
- 83
- Registration Number
- NCT05789069
- Locations
- 🇮🇹
Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Italy
🇺🇸New Experimental Therapeutics of Virginia - NEXT Oncology, Fairfax, Virginia, United States
🇪🇸Clinica Universidad de Navarra - Pamplona, Pamplona, Spain
A Study to Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients With mUC
- First Posted Date
- 2023-03-20
- Last Posted Date
- 2023-03-20
- Lead Sponsor
- Abbisko Therapeutics Co, Ltd
- Target Recruit Count
- 80
- Registration Number
- NCT05775874
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2023-03-16
- Last Posted Date
- 2023-03-16
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 25
- Registration Number
- NCT05771181
- Locations
- 🇨🇳
270 Dongan Road, Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in Locally Advanced NSCLC Patients
- Conditions
- Interventions
- First Posted Date
- 2023-03-07
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Peking University Cancer Hospital & Institute
- Target Recruit Count
- 20
- Registration Number
- NCT05758116
- Locations
- 🇨🇳
Peking University Cancer Hospital and Institute, Beijing, China
Tislelizumab Combined With Chemotherapy in the Cross-line Treatment of First-line Resistant Advanced Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-03-02
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 39
- Registration Number
- NCT05751265
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.